Adaptive Biotechnologies Corpor (ADPT) Stock Price & How to Invest

Adaptive Biotechnologies (NASDAQ: ADPT) runs an immune-medicine platform built around reading the genetics of the adaptive immune system. Its commercial engine is clonoSEQ, an FDA-cleared minimal residual disease (MRD) test that measures how many cancer cells remain in a patient during and after treatment, used mainly in blood cancers such as multiple myeloma, ALL, and CLL. The MRD segment now contributes roughly 95 percent of revenue and includes both clinical testing and pharma partnerships that use the platform in drug trials. A second Immune Medicine arm pursues drug discovery and includes a long-running collaboration with Genentech on neoantigen-directed T-cell therapies.

The investment picture is a diagnostics growth story reaching an inflection point. First-quarter 2026 revenue rose about 35 percent year over year to roughly $70.9 million, MRD revenue grew about 53 percent, and clonoSEQ test volume climbed about 41 percent, prompting management to raise full-year MRD guidance toward roughly $260 million to $270 million. Second-quarter revenue was about $71.6 million, up roughly 21.5 percent, but the net loss widened and EPS of -$0.25 was well below the -$0.13 consensus. Trailing revenue now stands near $308 million with a trailing net loss of about $64 million. In September 2026 the NCCN multiple myeloma guidelines were updated to strengthen MRD testing recommendations and specifically reference clonoSEQ, and the company pointed to the role of highly sensitive MRD testing in a new International Myeloma Society definition of cure. In June 2026 the company announced a plan to separate the profitable, scaled MRD business from the earlier-stage Immune Medicine unit, a move that could reshape how the two pieces are valued. The stock closed at $24.21 on October 16, 2026, up about 52 percent in 2026 and 40 percent over a year, below its 52-week high of $30.74.

ADPT still runs at a net loss on a consolidated basis (about $64 million over the trailing twelve months), so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. Debt of roughly $410 million exceeds cash of about $344 million at mid-2026. The MRD diagnostics market is competitive, with Natera, Guardant Health, Exact Sciences, and NeoGenomics all pushing MRD and liquid-biopsy offerings, and reimbursement decisions can swing revenue. Pharma milestone revenue is lumpy and hard to forecast quarter to quarter. The announced business separation adds execution and structural uncertainty, and the Immune Medicine drug programs, including the Genentech-linked work, are early stage with binary outcomes. Insiders sold shares in September and October 2026, according to SEC filings. The stock has also been volatile, trading between $12.00 and $30.74 over the past 52 weeks.

8 analysts publish price targets on ADPT, averaging $29.81 against a $24.02 price as of October 2026, or +24.1%. The published targets run from $21.00 to $35.00, a moderate spread, and the ratings split 8 buy, 1 hold, 0 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ADPT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Adaptive Biotechnologies Corpor. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. clonoSEQ MRD volume and reimbursement. The core driver is clonoSEQ test volume, which grew about 41 percent year over year in the first quarter of 2026 to more than 32,000 tests. The most optimistic published target, $35.00, assumes this works close to its best case.

The case against. ADPT still runs at a net loss on a consolidated basis (about $64 million over the trailing twelve months), so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. The most pessimistic target, $21.00, is roughly what ADPT is worth if this bites instead.

Read the full bull and bear case on ADPT, including what would have to change to break either one. Walnut is not an investment adviser.

No. Adaptive Biotechnologies Corpor (ADPT) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Adaptive Biotechnologies Corpor's investor relations page or your broker.

• Revenue (TTM): ~$308M (+~21.5% YoY latest qtr)
• Q2 2026 revenue: ~$71.6M
• 2026 MRD revenue guidance (raised after Q1): ~$260M to $270M
• Net loss (TTM): ~$64M (EPS ~-$0.41)
• Gross margin: ~47%
• Cash / debt: ~$344M / ~$410M
• Price-to-sales: ~12.5x
• Market cap: ~$3.9B

ADPT trades at about 12.5x trailing revenue, a high multiple typical of a growing, near-breakeven diagnostics company, and it has no meaningful earnings multiple since it remains unprofitable on a consolidated basis. Analysts expect 2026 revenue of about $293 million and 2027 revenue of about $359 million. The third-quarter report on November 4, 2026 (consensus revenue about $71.6 million and EPS of -$0.10) and any detail on the separation are the next catalysts.

Other names that sit close to ADPT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ADPT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ADPT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ADPT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

ADPT is a scaling MRD diagnostics business inside a still-unprofitable immune-medicine shell, with a planned split that could sharpen the investment case in either direction. Trailing revenue has passed $300 million and guideline support for MRD testing in myeloma grew in 2026, but the second quarter's wider-than-expected loss and a roughly 15% one-month pullback show how much of the good news the share price already carries.

Whether ADPT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ADPT a buy or a sell?, and where the stock could go from here in the ADPT stock forecast.

For income investors, whether ADPT pays a dividend and how the payout looks is covered in does ADPT pay a dividend? And to weigh ADPT against a peer, read the full side-by-side comparisons: ADPT vs GH and ADPT vs NEO.